Dr. Philippe Bedard | Bras DDP

Dr. Philippe Bedard

Claim this profile

Princess Margaret Cancer Centre

Studies Breast Cancer
Studies Cancer
16 reported clinical trials
27 drugs studied

Area of expertise

1Breast Cancer
Philippe Bedard has run 8 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
HER2 positive
Stage III
2Cancer
Philippe Bedard has run 8 trials for Cancer. Some of their research focus areas include:
Stage IV
HER2 positive
B7-H4 positive

Affiliated Hospitals

Image of trial facility.
Princess Margaret Cancer Centre
Image of trial facility.
University Health Network, Princess Margaret Hospital

Clinical Trials Philippe Bedard is currently running

Image of trial facility.

GSK4524101 + Niraparib

for Cancer

This trial is testing a new drug called GSK4524101 alone and with another drug called niraparib. It aims to find the highest safe dose and understand its effects, likely targeting cancer patients who need new treatment options. Niraparib is a drug taken by mouth that is used to maintain treatment in ovarian cancer.
Recruiting1 award Phase 1 & 24 criteria
Image of trial facility.

Disitamab Vedotin + Tucatinib

for Breast Cancer

This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer. Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are few treatment options for patients with advanced or metastatic solid tumors that express HER2. This clinical trial uses an experimental drug called disitamab vedotin (DV). Disitamab vedotin is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial uses a drug called tucatinib, which has been approved to treat cancer in the United States and some other countries. This drug is sold under the brand name TUKYSA®. This study will test how safe and how well DV with tucatinib works for participants with solid tumors. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.
Recruiting1 award Phase 26 criteria

More about Philippe Bedard

Clinical Trial Related4 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 8 Active Clinical Trials
Treatments Philippe Bedard has experience with
  • Tucatinib
  • Pembrolizumab
  • CFI-402257
  • GSK3745417
  • Placebo
  • T-DM1

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Philippe Bedard specialize in?
Is Philippe Bedard currently recruiting for clinical trials?
Are there any treatments that Philippe Bedard has studied deeply?
What is the best way to schedule an appointment with Philippe Bedard?
What is the office address of Philippe Bedard?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security